US Patent 10,702,536: Eslicarbazepine Acetate Once-Daily Dosing Claims and Patent Landscape

US Patent No. 10,702,536 protects once-daily administration of eslicarbazepine acetate for partial-onset seizures. Its broadest claims are method-of-treatment claims covering human patients, oral or other administration, single daily dosing, adjunctive use, specified doses, and pharmacokinetic exposure ranges.

The patent is commercially relevant to Aptiom, the branded eslicarbazepine acetate product marketed by Sunovion Pharmaceuticals, a subsidiary of Sumitomo Pharma. The principal enforcement issue is whether a generic product label instructs once-daily treatment for partial-onset seizures at a covered dose or with the claimed exposure profile.

What patent protects once-daily eslicarbazepine acetate treatment?

US 10,702,536 contains two independent method claims.

Claim	Core protection	Practical scope
1	Once-daily administration of a composition consisting essentially of eslicarbazepine acetate to a human with partial-onset seizures	Broadest dose-independent treatment claim
28	Treating partial-onset seizures by producing a higher eslicarbazepine Cmax through once-daily dosing rather than dividing the same total amount twice daily	Comparative pharmacokinetic claim

Claim 1 requires four principal elements:

A human patient.
Partial-onset seizures.
A pharmaceutical composition consisting essentially of eslicarbazepine acetate.
Once-daily administration that is pharmacologically effective.

The claim does not require a particular tablet strength, formulation technology, adjunctive drug, Cmax, AUC, or clinical response threshold. The dependent claims add those limitations.

Claim 28 is materially different. It does not expressly require a composition consisting essentially of eslicarbazepine acetate. Instead, it focuses on the pharmacokinetic consequence of administering the total daily amount once rather than dividing it twice daily. The claim requires a higher rate of exposure measured by Cmax.

How broad is claim 1 of US 10,702,536?

Claim 1 is the principal infringement risk because it is not limited to the 800 mg or 1,200 mg strengths used in ordinary Aptiom titration. It covers once-daily administration of eslicarbazepine acetate at any pharmacologically effective amount, provided the remaining claim elements are satisfied.

The claim is limited in several important ways:

It applies to partial-onset seizures, rather than all epilepsy indications.
It requires a human patient.
It requires once-daily administration.
It requires a pharmaceutical composition.
The composition must consist essentially of eslicarbazepine acetate.
The administration must be pharmacologically effective.

A product supplied for twice-daily dosing would not ordinarily satisfy the once-daily limitation. A product indicated only for another seizure type would create a separate claim-scope question. A label that recommends once-daily treatment for partial-onset seizures presents a stronger literal-infringement case.

The phrase "consisting essentially of" is narrower than "comprising" but broader than "consisting of." It generally permits excipients and other components that do not materially affect the basic and novel characteristics of the composition. Standard tablet excipients, coatings, binders, fillers, and disintegrants would not normally remove a product from the claim.

What doses are protected by US 10,702,536?

Claims 2 through 12 cover specific dosing ranges and titration schedules.

Claim	Dose limitation
2	At least about 400 mg once daily
3	At least about 800 mg once daily
4	At least about 1,200 mg once daily
5	About 800 mg to about 2,400 mg once daily
6	About 200 mg once daily
7	About 400 mg once daily
8	About 600 mg once daily
9	About 800 mg once daily
10	About 1,200 mg once daily
11	About 2,400 mg once daily
12	Initial dose of about 400 mg, increased to about 800 mg or 1,200 mg

The overlapping claims create multiple routes to infringement. For example, an 800 mg once-daily regimen may fall within:

Claim 1;
Claim 2;
Claim 3;
Claim 5;
Claim 9; and
potentially claim 12 if preceded by a 400 mg initiation dose.

The "about" terminology introduces ordinary claim-construction flexibility around the stated numerical values. The overlap is commercially important because a generic label does not need to reproduce the exact branded titration wording to implicate the patent. A label recommending 800 mg once daily after an initial lower dose could satisfy several claims.

The 2,400 mg limitation is broader than the labeled maximum dose for ordinary Aptiom treatment in many patients. It may nevertheless cover clinical or investigational regimens and does not necessarily determine the practical generic-launch risk.

Does the patent cover adjunctive therapy with valproate or lamotrigine?

Yes. Claims 13 through 15 cover once-daily eslicarbazepine acetate administered as adjunctive therapy with another antiepileptic drug.

Claim 15 specifically identifies:

Valproate;
Lamotrigine;
Topiramate; and
Combinations of those drugs.

Claim 14 adds a pharmacological interaction limitation. The serum concentration of the other antiepileptic drug must not be significantly decreased by once-daily eslicarbazepine acetate administration.

These claims are narrower than claim 1 because they require adjunctive treatment. They may be relevant where a generic label expressly instructs use with one of the listed antiepileptic drugs. They also create potential evidentiary issues because "significantly decreased" requires a comparison against a baseline or control condition.

What formulations and routes of administration are protected?

Claim 16 identifies tablets and oral suspensions. Claim 18 requires oral administration. Claim 20 requires the full daily dose to be contained in a single dosage unit.

The formulation coverage is functional rather than technology-specific. The patent does not, based on the supplied claims, require:

A particular excipient;
A particular dissolution profile;
A controlled-release matrix;
A specific particle size;
A coating system;
A particular polymorph; or
A manufacturing process.

This distinction matters. US 10,702,536 is principally a dosing and treatment patent, not a conventional formulation-composition patent. A generic tablet using different excipients could still fall within claims 1, 16, 18, or 20 if it is administered once daily to treat partial-onset seizures.

What pharmacokinetic ranges are claimed?

Claims 19 and 21 through 30 cover steady-state exposure, AUC, Cmax, and the pharmacokinetic difference between once-daily and twice-daily administration.

Claim	Pharmacokinetic limitation
19	Steady-state eslicarbazepine concentrations after 4 to 5 days
21	AUC0-τ of about 2,400 to 507,600 ng·h/mL; 24-hour dosing interval
22	AUC0-τ of about 126,300 to 905,900 ng·h/mL; claim text uses "T" for the dosing interval
23	Maximum observed Cmax up to about 56,500 ng/mL
24	Mean Cmax of about 8,800 to 56,500 ng/mL
25	Mean Cmax of about 18,000 to 34,600 ng/mL
26	Cmax of about 8,500 to 18,600
27	Maximum observed Cmax of about 2,900 to 15,000
29	Cmax up to about 56,500 ng/mL
30	Cmax of about 1,500 to 35,900 ng/mL

Claims 21 and 22 contain unusually broad and overlapping AUC ranges. Claim 22 also uses "T" while defining the dosing interval elsewhere as 24 hours. That drafting issue may be relevant to claim construction, indefiniteness arguments, or validity analysis, depending on how the court interprets the specification and prosecution history.

Claims 26 and 27 omit the unit after the Cmax ranges in the supplied text. The specification and prosecution record would ordinarily be consulted to determine whether the missing unit is understood as ng/mL and whether the omission creates a material indefiniteness issue.

The pharmacokinetic claims are difficult to assess solely from a product label. They may require:

Clinical pharmacokinetic data;
Population pharmacokinetic modeling;
Therapeutic-equivalence studies;
Batch or formulation data; or
Discovery obtained in litigation.

How does claim 28 differ from claim 1?

Claim 28 targets the pharmacokinetic advantage of once-daily dosing. It requires the patient to be exposed to a higher rate of eslicarbazepine exposure, measured by Cmax, than would result from administering the same total amount divided twice daily.

This claim has three distinctive features:

It requires a comparison with twice-daily dosing.
It focuses on Cmax rather than merely the dosing schedule.
It does not expressly require the same composition language used in claim 1.

A product could therefore face claim 28 risk even where the dispute centers on the pharmacokinetic effect of the dosing regimen rather than the composition itself. The comparison must be scientifically supported. A generic applicant could challenge the claim by arguing that the proposed regimen does not produce the required higher Cmax, that the comparison is not made using the same total amount, or that the claim lacks adequate support or definiteness.

When does US 10,702,536 lose exclusivity?

US 10,702,536 is associated with the Aptiom patent estate and has an Orange Book-listed patent term extending into 2027. The commonly reported expiration date for the relevant Aptiom patent family is March 20, 2027, subject to any applicable patent-term adjustment, pediatric exclusivity, terminal-disclaimer effects, or later regulatory developments.[1][2]

Milestone	Date or status
Patent	US 10,702,536
Grant	July 7, 2020
Product	Aptiom, eslicarbazepine acetate
Regulatory pathway	NDA 021842
Patent type	Method of treatment and pharmacokinetic dosing
Reported patent-term endpoint	March 20, 2027
Potential pediatric protection	FDA Orange Book records must be checked for any applicable extension
Generic pathway	ANDA under section 505(j)

Patent expiration does not necessarily equal the earliest generic launch date. An ANDA applicant may obtain approval before expiration with a Paragraph IV certification, subject to litigation, a 30-month stay, settlement terms, and any non-patent exclusivity.

What is the Orange Book status of the Aptiom patent estate?

Aptiom is an FDA-approved small-molecule drug, so the relevant competitive pathway is generic substitution through an ANDA, not biosimilar approval through a biologics license application.

The Orange Book patent landscape for Aptiom has included multiple patent families covering different aspects of the product, including:

The active pharmaceutical ingredient;
Eslicarbazepine acetate formulations;
Dosing regimens;
Methods of treating epilepsy; and
Pharmacokinetic or administration characteristics.

US 10,702,536 is important because its claims reach the labeled once-daily treatment regimen rather than merely a chemical compound or manufacturing process. A generic applicant that seeks a label for once-daily treatment may need to address this patent directly.

An ANDA applicant can pursue several strategies:

Paragraph III certification, delaying approval until patent expiration;
Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed;
A section viii statement carving out patented methods from the proposed label; or
A label that omits the patented indication or dosing instructions, if FDA requirements permit.

For a drug whose central FDA-approved use is once-daily treatment of partial-onset seizures, a complete carve-out may be difficult. The commercial value of the product depends on preserving the once-daily epilepsy indication.

Which companies are challenging Aptiom patents?

The relevant challengers are generic drug companies filing ANDAs for eslicarbazepine acetate. Public FDA records have identified generic applicants and approved products over time, but the specific Paragraph IV certification and litigation posture must be evaluated patent by patent.

The commercial challenge is primarily from generic manufacturers rather than biosimilar developers. Eslicarbazepine acetate is a chemically synthesized small molecule and is not a biologic. Biosimilar approval under the Public Health Service Act is therefore not the applicable route.[3]

The litigation record should be separated into four categories:

Issue	Relevance
ANDA filing	Establishes the applicant's proposed product and certification
Paragraph IV notice	Starts the patent-holder's litigation window
District-court litigation	Determines infringement, validity, and enforceability
Settlement agreement	May establish an agreed generic launch date before patent expiration

A settlement can materially change launch timing without invalidating the patent. The absence of a publicly reported invalidity judgment does not itself establish that every claim is enforceable against every generic formulation.

What generic entry risks exist for eslicarbazepine acetate?

The highest-risk scenario for the patent holder is a generic label that mirrors Aptiom's once-daily dosing instructions for partial-onset seizures.

High-risk generic conduct

Once-daily treatment of partial-onset seizures;
800 mg or 1,200 mg daily dosing;
Initial 400 mg dosing followed by escalation;
A single tablet containing the full daily dose;
Oral tablet administration;
Adjunctive use with other antiepileptic drugs.

Lower-risk or design-around scenarios

A label that omits once-daily dosing;
A product limited to a non-covered indication, if clinically and regulatorily feasible;
A formulation that cannot be shown to meet the claimed composition or exposure limitations;
A section viii carve-out of the patented method;
A dosing schedule that is not once daily, although this may reduce commercial substitutability.

A design-around based only on different excipients is unlikely to avoid claim 1 if the product remains a pharmaceutical composition consisting essentially of eslicarbazepine acetate administered once daily.

How strong is the patent estate for Aptiom?

The estate is strongest where the branded and generic labels overlap directly. Claim 1 is broad and commercially aligned with the central once-daily use. Claims 2 through 12 provide dose-specific fallback positions. Claims 13 through 20 add adjunctive, formulation, route, and single-unit limitations. Claims 21 through 30 create additional pharmacokinetic positions.

Potential vulnerability points include:

The meaning of "consisting essentially of";
The scope of "pharmacologically effective";
The treatment definition for partial-onset seizures;
The written-description and enablement support for broad exposure ranges;
The numerical overlap and terminology in claims 21 and 22;
The missing units in claims 26 and 27 as supplied;
The comparative requirement in claim 28; and
Whether once-daily administration inherently produces the claimed Cmax.

The patent's practical strength is therefore greater for ordinary branded-label use than for every conceivable eslicarbazepine acetate regimen.

What manufacturing and intellectual-property barriers remain?

US 10,702,536 does not itself appear, from the supplied claims, to require a proprietary manufacturing process. Its principal barrier is the use instruction and pharmacokinetic regimen.

Other patent families may create separate risks involving:

Eslicarbazepine acetate synthesis;
Enantiomeric purity;
Crystalline forms;
Tablet manufacture;
Dissolution and stability;
Oral suspensions;
Drug-excipient compatibility; and
Commercial-scale production.

A generic company that clears the dosing patent may still need a separate freedom-to-operate analysis covering API manufacture and formulation patents in the United States, Europe, Japan, and other regulated markets.

How does Aptiom compare with competing antiseizure drugs?

Product	Active ingredient	Typical dosing structure	Generic or biosimilar issue
Aptiom	Eslicarbazepine acetate	Once daily	ANDA and method-of-use patent risk
Trileptal	Oxcarbazepine	Usually divided dosing	Generic competition established
Tegretol	Carbamazepine	Often divided dosing	Generic competition established
Lamictal	Lamotrigine	Once or twice daily depending on regimen	Generic competition established
Keppra	Levetiracetam	Often twice daily, with extended-release once daily	Generic competition established

Aptiom's patent exposure is concentrated in the once-daily treatment regimen. That gives the patent estate commercial relevance but also creates a potential section viii issue: if the once-daily indication is the principal approved use, a meaningful label carve-out may be difficult.

What revenue exposure does the patent create?

The revenue exposure is tied to the timing of generic entry, not only to the nominal expiration date. Once a substitutable generic launches, branded volume and net pricing can decline rapidly, particularly for a small-molecule product with an established ANDA pathway.

The most valuable protected features are:

Once-daily administration;
800 mg and 1,200 mg dosing;
Oral tablet delivery;
Initial-dose escalation;
Use as adjunctive therapy; and
The commercially familiar Aptiom treatment label.

The patent does not protect all eslicarbazepine acetate sales independently of dosing instructions. Its economic value depends on whether competing applicants can obtain approval with a label that avoids the claimed methods.

Key Takeaways

US 10,702,536 is a method-of-treatment patent centered on once-daily eslicarbazepine acetate for partial-onset seizures.
Claim 1 is the broadest practical claim and is not limited to a specific dose.
Claims 2 through 12 cover 200 mg to 2,400 mg dosing and common titration schedules.
Claims 13 through 20 cover adjunctive therapy, oral administration, tablets, oral suspensions, and single-unit daily dosing.
Claims 21 through 30 add AUC, Cmax, steady-state, and once-daily-versus-twice-daily exposure limitations.
The patent is relevant to Aptiom and the ANDA pathway for generic eslicarbazepine acetate.
Eslicarbazepine acetate is a small molecule, so biosimilar risk is not applicable.
The reported patent-term endpoint is March 20, 2027, subject to applicable regulatory and patent-term adjustments.
The strongest infringement scenario is a generic label that reproduces once-daily treatment of partial-onset seizures at 800 mg or 1,200 mg.
The most material validity and enforcement issues concern claim construction, pharmacokinetic proof, the broad numerical ranges, and the wording of claims 21, 22, 26, 27, and 28.

FAQs

Does US 10,702,536 cover the Aptiom 800 mg tablet?

Yes, if the 800 mg tablet is administered once daily to a human patient for partial-onset seizures. That regimen may fall within claims 1, 2, 3, 5, and 9.

Can a generic company avoid the patent by changing tablet excipients?

Usually not if the product remains a once-daily eslicarbazepine acetate composition used to treat partial-onset seizures. Different excipients would not necessarily avoid the "consisting essentially of" limitation.

Is a twice-daily eslicarbazepine acetate product outside the patent?

It is less likely to satisfy the once-daily limitation in claims 1 through 27. It would also face a stronger defense to claim 28 because that claim specifically compares once-daily administration with divided twice-daily dosing.

Does the patent cover eslicarbazepine itself or only eslicarbazepine acetate?

The claims supplied focus on a pharmaceutical composition consisting essentially of eslicarbazepine acetate, while the pharmacokinetic results are measured using eslicarbazepine. The distinction matters for claim construction and cannot be treated as a general patent on every use of eslicarbazepine.

Can FDA approve a generic before the patent expires?

Yes. An ANDA applicant may obtain approval before patent expiration after a Paragraph IV certification, subject to patent litigation, a statutory stay, settlement terms, and any other applicable exclusivity.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,702,536, methods of treating partial-onset seizures with eslicarbazepine acetate. USPTO.
U.S. Food and Drug Administration. (2024). Generic drugs and biologics: ANDA and biosimilar approval pathways. FDA.
Sunovion Pharmaceuticals Inc. (2013). Aptiom (eslicarbazepine acetate) prescribing information. U.S. Food and Drug Administration.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055939	⤷ Start Trial
Australia	2005331690	⤷ Start Trial
Brazil	PI0520258	⤷ Start Trial
Canada	2607427	⤷ Start Trial
Mexico	2007013882	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,702,536

Summary for Patent: 10,702,536